NCT04113096

Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer

Use of Dibenzyl Trisulphide as a Chemotherapeutic Agent in Stage Four Cancer of the Breast, Prostate, Cervix and Colon

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 104 (estimated)
• Sponsor: The University of The West Indies · Academic / Other
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to find the effect of Dibenzyl Trisulphide (active ingredient in Guinea Hen Weed in combination in patients with stage four cancer of the breast, prostate, cervix and colon.

Detailed description

There have been many claims of the value of Guinea Hen weed in the treatment of different cancers. The preparation is readily available and used locally. The team proposes to validate the studies done on cancer cell lines by conducting a clinical trial to determine the clinical benefit in advanced and metastatic cancers.

Conditions

• Stage IV Prostate Cancer
• Stage IV Colon Cancer
• Stage IV Breast Cancer
• Stage IV Cancer of the Cervix

Interventions

Type	Name	Description
DRUG	Dibenzyl trisulphide capsules	20 mg once daily for 6 months
DRUG	Dibenzyl trisulphide capsules	20 mg once daily for 6 months
DRUG	Dibenzyl trisulphide capsules	20 mg once daily for 6 months
DRUG	Dibenzyl trisulphide capsules	20 mg once daily for 6 months
DRUG	Stage IV Breast Cancer Placebo	20 mg once daily for 6 months
DRUG	Stage IV: Colon Cancer Placebo	20 mg once daily for 6 months
DRUG	Cervical Cancer Stage IV Placebo	20 mg once daily for 6 months
DRUG	Cancer of the Prostate Placebo	20 mg once daily for 6 months

Timeline

• Start date: 2018-10-01
• Primary completion: 2020-09-30
• Completion: 2020-09-30
• First posted: 2019-10-02
• Last updated: 2019-10-08

Locations

1 site across 1 country: Jamaica